Literature DB >> 31558234

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

Ibiayi Dagogo-Jack1, Zofia Piotrowska1, Rosemary Cobb1, Mandeep Banwait1, Jochen K Lennerz2, Aaron N Hata1, Subba R Digumarthy1, Lecia V Sequist3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31558234     DOI： 10.1016/j.jtho.2019.05.046

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

Review 1.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

Review 2.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

3.  MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.

Authors:  Jiajia Gu; Weilong Yao; Puyu Shi; Guojing Zhang; Taofeek K Owonikoko; Suresh S Ramalingam; Shi-Yong Sun
Journal:  Cancer       Date:  2020-06-04       Impact factor: 6.860

4.  Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.

Authors:  Maurício Fernando Silva Almeida Ribeiro; Franciele Hinterholz Knebel; Fabiana Bettoni; Rodrigo Saddi; Karina Perez Sacardo; Felipe Sales Nogueira Amorim Canedo; João Victor Machado Alessi; Andrea Kazumi Shimada; José Flávio Gomes Marin; Anamaria Aranha Camargo; Artur Katz
Journal:  NPJ Precis Oncol       Date:  2021-02-12

Review 5.  Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.

Authors:  Alejandro Ríos-Hoyo; Laura Moliner; Edurne Arriola
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

Review 6.  The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.

Authors:  Longyao Zhang; Linpeng Zheng; Qiao Yang; Jianguo Sun
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

7.  Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.

Authors:  Wu Chen; Danlei Yu; Shi-Yong Sun; Feng Li
Journal:  Acta Biomater       Date:  2021-05-25       Impact factor: 10.633
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.